SEPN Stock Analysis: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$36.57
1.72 (4.94%)
▲
5d:
+1.5%
30d:
+30.98%
90d:
+53.78%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SEPN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SEPN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $36.57, which is considered extended relative to its 30-day fair value range of $28.44 to $34.61.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $37.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: SEPN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.78 (+25.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $37.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: SEPN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.78 (+25.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.44 -
$34.61
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 25.2% below Wall St target ($45.78)
Trading Range Analysis
30-Day Trading Range
$28.44 -
$34.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$30.24
Resistance Level
$37.32
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.75
Wall Street Target
$45.78
(+25.2%)
Revenue Growth (YoY)
12011.0%
Profit Margin
-49.9%
Share & Embed Analysis
Last updated: June 24, 2026 6:54 AM ET
Data refreshes hourly during market hours. Next update: 7:54 AM
Data refreshes hourly during market hours. Next update: 7:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Elizabeth Bhatt
SELL
4000 shares
2026-04-15
Samira Shaikhly
SELL
70453 shares
2026-03-02
Elizabeth Bhatt
SELL
4000 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
